Objective: Neonatal sepsis (NS) is a common and life-threatening disorder in infants. Previous studies showed that interleukin-6 (IL-6) may be a valid non-invasive and rapid method for diagnosis of NS. We conducted this review to assess the validity of IL-6 for predicting NS.
Methods: This was a systematic review with meta-analysis. Embase, Medline and Web of Science databases were searched between January 1990 and December 2009. The search terms used were "cytokine", "neonate", "sepsis" and "interleukin-6". We used standard methods recommended for meta analyses of diagnostic test evaluations. The analysis was based on a summary ROC (SROC) curve. Meta-regression analysis was used to assess the effects of some confounding factors on the results of meta-analysis. Potential presence of publication bias was tested using funnel plots and the Egger test.
Findings: Meta-analysis was performed on 13 publications including 353 infants with sepsis and 691 control infants. The pooled sensitivity and specificity of IL-6 was 0.79 and 0.84, respectively. The maximum joint sensitivity and specificity (i.e., the Q value) in SROC curve was 0.82 and the area under curve (AUC) was 0.89 (95% CI: 0.84-0.94). Meta-regression analysis showed that the diagnostic accuracy of IL-6 was not affected by confounding variables. The evaluation of publication bias showed that the Egger test was not significant (P=0.07).
Conclusion: IL-6 seems to be a valid marker for predicting NS. It may be considered for early diagnosis of sepsis in neonatal care units.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446138 | PMC |
Eur J Pharm Sci
January 2025
Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Electronic address:
Tacrolimus is extensively used for the prevention of graft rejection following solid organ transplantation in pregnant women. However, knowledge gaps in the dosage of tacrolimus for pregnant patients with different CYP3A5 genotypes and infection conditions have been identified. This study aimed to develop a pregnant physiologically based pharmacokinetic (PBPK) model to characterize the maternal and fetal pharmacokinetics of tacrolimus during pregnancy and explore and provide dosage adjustments.
View Article and Find Full Text PDFBackground: Cardiovascular-kidney-metabolic (CKM) health, a term recently defined by the American Heart Association, encompasses the interplay among metabolic, chronic kidney, and cardiovascular risk factors. We aimed to investigate the predictive significance of CKM disorders with the risk of cognitive decline and Alzheimer's disease (AD) and AD-related dementia (ADRD) mortality in a multiethnic population.
Method: We analyzed a cohort of 6,440 adults aged 45-84 who participated in the Multiethnic Study of Atherosclerosis, with a baseline survey conducted in 2000-2002, and were followed through to December 2015.
Alzheimers Dement
December 2024
University of Iowa College of Nursing, Iowa City, IA, USA.
Background: Accumulation of β-amyloid (Aβ) and tau proteins can predict the risk of Alzheimer's disease (AD) at asymptomatic stages and are promising measures for screening individuals at risk. However, not all individuals with Aβ and tau pathology progress to AD; some remain cognitively healthy. That variability challenges prediction accuracy and incorporation of AD pathology into clinical practice.
View Article and Find Full Text PDFJ Child Neurol
January 2025
Department of pediatrics, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
This review evaluated the correlation between inflammatory response and clinical outcomes in pediatric patients with meningitis. PubMed, Scopus, and Web of Science were searched for relevant studies published until March 2024. A total of 139 articles were identified; 7 studies were eligible, and 3 provided data for the meta-analysis.
View Article and Find Full Text PDFBackground: Apathy in Alzheimer's disease improves with methylphenidate (MPH) but treatment response was found to vary depending on clinical factors. Here, we explored whether underlying biological factors assessed by blood-based biomarkers of neurodegeneration, inflammation and oxidative stress affect apathy treatment response.
Method: A subset of participants from the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) were included in this study whose blood samples were available at baseline and at the 6-month treatment completion.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!